BRIEF published on 05/14/2024 at 22:26, 1 year 11 months ago Bausch Health annonce des mises à jour sur le litige Norwich XIFAXAN et une nouvelle soumission à la FDA XIFAXAN Bausch Santé Contentieux Des Brevets Norwich Pharmaceutique Soumission À La FDA
BRIEF published on 05/14/2024 at 22:20, 1 year 11 months ago Sonnet BioTherapeutics Announces Fiscal Year 2024 Q2 Results and Business Updates Financial Results Clinical Trials Oncology Biopharmaceuticals Sonnet BioTherapeutics
BRIEF published on 05/14/2024 at 22:20, 1 year 11 months ago Sonnet BioTherapeutics annonce ses résultats du deuxième trimestre de l'exercice 2024 et des mises à jour sur ses activités Résultats Financiers Essais Cliniques Oncologie Sonnet BioTherapeutics Produits Biopharmaceutiques
BRIEF published on 05/14/2024 at 22:20, 1 year 11 months ago NANOBIOTIX Lance une Étude de Phase 2 sur le Traitement du Cancer du Poumon avec FDA Approval FDA Étude De Phase 2 NANOBIOTIX Cancer Du Poumon NBTXR3
BRIEF published on 05/14/2024 at 22:20, 1 year 11 months ago NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
BRIEF published on 05/14/2024 at 22:15, 1 year 11 months ago GENFIT Announces Q1 2024 Financials and Projects Cash Runway into Late 2025 Cash Position Clinical Trials Revenue Decline Biopharmaceutical Industry GENFIT Financial Results
BRIEF published on 05/14/2024 at 22:15, 1 year 11 months ago GENFIT annonce ses résultats financiers du premier trimestre 2024 et dispose d'une trésorerie disponible jusqu'à fin 2025 Industrie Biopharmaceutique Essais Cliniques Baisse Des Revenus Résultats Financiers De GENFIT Situation De Trésorerie
BRIEF published on 05/14/2024 at 22:10, 1 year 11 months ago Protagonist Therapeutics to Present New Rusfertide Study Data at EHA Congress 2024 Clinical Study Protagonist Therapeutics Rusfertide Polycythemia Vera EHA Congress 2024
BRIEF published on 05/14/2024 at 22:10, 1 year 11 months ago Protagonist Therapeutics présentera de nouvelles données de l'étude Rusfertide au congrès de l'EHA 2024 Étude Clinique Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Congrès EHA 2024
BRIEF published on 05/14/2024 at 22:10, 1 year 11 months ago Vicinity Motor Corp. Reports Strong First Quarter 2024 Financial Results Financial Results Revenue Growth Electric Vehicles Market Expansion Vicinity Motor Corp
Published on 04/24/2026 at 15:00, 3 hours 22 minutes ago Norsemont Reports Significant Copper, Lead & Zinc Values in Three Choquelimpie Drill Holes
Published on 04/24/2026 at 15:00, 3 hours 22 minutes ago First Canadian Graphite Appoints Scott Kelly As Chief Financial Officer
Published on 04/24/2026 at 14:30, 3 hours 52 minutes ago Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Published on 04/24/2026 at 14:00, 4 hours 22 minutes ago Datametrex Expands Patent Monetization Strategy Adding Quantum-Resilient Encryption Technologies
Published on 04/24/2026 at 13:30, 4 hours 52 minutes ago Alset AI Announces Closing of Second Tranche of Loan Transaction of up to $3 Million
Published on 04/24/2026 at 18:12, 9 minutes ago EQS-Adhoc: clearvise AG reviews dividend proposal in line with its dividend strategy and postpones Annual General Meeting
Published on 04/24/2026 at 18:07, 14 minutes ago DEAG sets new records for revenue and earnings in financial year 2025 – excellently positioned for long-term growth
Published on 04/24/2026 at 18:05, 16 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/24/2026 at 18:00, 22 minutes ago SMTPC - Communiqué sur la mise à disposition du Rapport annuel 2025
Published on 04/24/2026 at 17:45, 37 minutes ago Imerys-04-2026-information-share-capital-and-voting-rights-as-of-31-March-2026
Published on 04/24/2026 at 17:45, 37 minutes ago Imerys-04-2026-communique-capital-droits-de-vote-au-31-mars-2026
